Downregulation of CASP3 gene expression has been observed to be associated with various malignancies, and promoter polymorphisms in the CASP3 gene may have a great impact on the CASP3 transcriptional activity. The present study aimed to analyze the possible impact of the CASP3 (−1337 C > G, rs1405937) polymorphism on the expression profile of CASP3 gene and ultimately its association in the development of non-small cell lung cancer. A case–control study of 100 non-small cell lung cancer patients and 100 cancer free healthy controls was conducted, wherein genotype and expression profile of CASP3 gene were evaluated using serum DNA and serum RNA, respectively, by primer-introduced restriction fragment analysis and real-time PCR techniques. Compared to the CASP3 CC genotype, odds ratio of 11.1 was found to be associated to the homozygous GG genotype with more than sixfold decrease of CASP3 gene expression in non-small cell lung cancer patients. Significant trend of decrease in caspase 3 expression was observed with the increase in severity of the disease. Patients with CASP3 (−1337GG) genotype had significantly shorter overall survival compared to CASP3 (−1337CC) genotype carriers. In addition, significantly poor overall survival was also reflected by patients with higher fold decrease in CASP3 gene expression. CASP3 (−1337 GG) genotype was found to be associated with significantly lower CASP3 gene expression especially among patients with advanced status of the disease, suggesting that CASP3 (−1337C > G) polymorphism may be involved in the development and progression of non-small cell lung cancer.
Non-small cell lung cancer CASP3 (−1337 C > G) polymorphism CASP3 gene expression
Non-small cell lung cancer
Caspase 3 gene
Squamous cell carcinoma
This is a preview of subscription content, log in to check access.
The authors specially thank all of the patients who participated in this study.
Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention 3rd ed. OUP USA 2006 pp 638–658.Google Scholar
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39:605–13.CrossRefPubMedGoogle Scholar
MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004;96:1866–9.CrossRefPubMedGoogle Scholar
Hu Z, Li C, Chen K, Wang L-E, Wei Q. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol. 2008;2008:147905.CrossRefPubMedPubMedCentralGoogle Scholar
Chang MW, Lo JM, Juan HF, Chang HY, Chuang CY. Combination of RGD compound and low-dose paclitaxel induces apoptosis in human glioblastoma cells. PLoS One. 2012;7(5), e37935.CrossRefPubMedPubMedCentralGoogle Scholar
Wang JX, Zheng S. Caspase 3 and survivin expression in pediatric neuroblastoma and their roles in apoptosis. Chin Med J. 2004;117:1821–4.PubMedGoogle Scholar
Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21:8843–51.CrossRefPubMedGoogle Scholar
Isobe N, Onodera H, Mori A, Shimada Y, Yang W, Yasuda S, et al. Caspase 3 expression in human gastric carcinoma and its clinical significance. Oncology. 2004;66(3):201–9.CrossRefPubMedGoogle Scholar
Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61(3):1227–32.PubMedGoogle Scholar
Xu M, Xia LP, Fan LJ, Xue JL, Shao WW, Xu D. Livin and caspase-3 expression are negatively correlated in cervical squamous cell cancer. Eur J Gynaecol Oncol. 2013;34(2):152–5.PubMedGoogle Scholar
Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 2001;61(1):348–54.PubMedGoogle Scholar
Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, et al. Involvement of CPP32/Yama(−like) proteases in Fas-mediated apoptosis. Cancer Res. 1996;56(8):1713–8.PubMedGoogle Scholar
Silke J, Ekert PG, Day CL, Hawkins CJ, Baca M, Chew J, et al. Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. EMBOJ. 2001;20(12):3114–23.CrossRefGoogle Scholar
Widiana IK, Wibawa-M I, Siki-Kawiyana K, Sutirta-Yasa I. Changes of mRNA Caspase-3 after first cycle of chemotherapy as biomarker associate to chemotherapy negative response in locally advanced breast cancer. Bali Med J. 2015;4(2):53–5.CrossRefGoogle Scholar